Knight Therapeutics Inc.
KHTRF
$5.32
$0.030.57%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 95.48M | 88.25M | 77.59M | 61.37M | 69.20M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 95.48M | 88.25M | 77.59M | 61.37M | 69.20M |
| Cost of Revenue | 49.05M | 47.73M | 45.19M | 37.08M | 40.37M |
| Gross Profit | 46.43M | 40.52M | 32.40M | 24.29M | 28.83M |
| SG&A Expenses | 25.43M | 22.52M | 22.76M | 18.22M | 18.09M |
| Depreciation & Amortization | 9.92M | 11.21M | 7.76M | 6.60M | 7.59M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 91.02M | 87.78M | 80.25M | 65.23M | 71.31M |
| Operating Income | 4.45M | 469.00K | -2.65M | -3.86M | -2.11M |
| Income Before Tax | 8.05M | -1.39M | -11.28M | -278.00K | 5.63M |
| Income Tax Expenses | 1.70M | 1.36M | -2.16M | -1.80M | -2.04M |
| Earnings from Continuing Operations | 6.35M | -2.75M | -9.12M | 1.52M | 7.67M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 6.35M | -2.75M | -9.12M | 1.52M | 7.67M |
| EBIT | 4.45M | 469.00K | -2.65M | -3.86M | -2.11M |
| EBITDA | 11.81M | 13.37M | 6.12M | 4.21M | 4.62M |
| EPS Basic | 0.06 | -0.03 | -0.09 | 0.02 | 0.08 |
| Normalized Basic EPS | 0.01 | 0.01 | -0.05 | 0.00 | -0.01 |
| EPS Diluted | 0.06 | -0.03 | -0.09 | 0.01 | 0.07 |
| Normalized Diluted EPS | 0.01 | 0.01 | -0.05 | 0.00 | -0.01 |
| Average Basic Shares Outstanding | 99.34M | 99.66M | 99.63M | 99.64M | 100.53M |
| Average Diluted Shares Outstanding | 99.86M | 99.66M | 99.63M | 100.08M | 100.94M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |